Thus, a direct role for CB1R antagonism on adipocytes does not require brain penetrance, supporting the importance of pursuing peripheral CB1R antagonism for the pharmacological treatment of obesity, T2D, and related metabolic diseases. Here, CNR1 is linked to Other metabolic disease.